Repligen Corporation (RGEN)
Nasdaq · Healthcare · Medical Instruments & Supplies
$189.50+4.29%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.7B
- P/E (trailing)
- 259.6
- Forward P/E
- 71.5
- 52-week range
- $100.99 – $198.87
- 52-week change
- +21.05%
- EPS (trailing)
- $0.73
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $738M (+16.36%)
- Net income
- $48.9M
- Operating margin
- 7.5%
- Diluted EPS
- $0.86
- Free cash flow
- $93.9M
From the company’s annual report on SEC EDGAR.
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits.
Headquarters: Waltham, United States · 2,000 employees · repligen.com